Long-term analysis of a Phase 2 RCT | Fulvestrant plus capivasertib vs. placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive, HER2-negative breast cancer.
11 Jul, 2022 | 11:48h | UTCNews Release: New phase of breast cancer drug trial provides fresh hope for patients with incurable disease – Cardiff University